Form D · Biotechnology
NX Pharmagen Inc.
Louisville, KY · CIK 0001508691
Offering snapshot reported Oct 21, 2022 · SEC filing
- Reported sold
- $590K Offering amount: $1M
- Investors reported
- 19 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 10, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 21, 2022 | Initial | $590,000 | No comparison | 19 | SEC filing |
| Aug 31, 2020 | Initial | $486,000 | No comparison | 13 | SEC filing |
| Jun 25, 2013 | Initial | $773,000 | No comparison | 0 | SEC filing |
| Dec 28, 2010 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-462445
Source: Form D, filed Oct 21, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Brian Brohman | Director, Executive |
| Pascal Deschatelets | Director |
| Alan Ezrin | Director |
| Cedric Francois | Director |
| Fred Mermelstein | Director |
| Robert Saunders | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4350 Brownsboro Road Suite 110
Louisville, KY, 40207
Louisville, KY, 40207